Balanced news tone
News Sentiment
42C sentiment intelligence
iX Biopharma Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
47
Balanced news tone
17 relevant articles
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+8.2% over one week, +14.5% over four weeks, trend active, and materially above fair value.
iX Biopharma Sets July 2026 Expiry for S$0.06 Warrants
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
83/100 classification
One-week reaction
8.2%
Price confirming higher
Trend fit
Trend active
14.5% over four weeks
Fair value
405.3%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
4
Neutral
8
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TipRanks
Direct company coverage
iX Biopharma Sets July 2026 Expiry for S$0.06 Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2026 05:18
- Source
- TipRanks
TipRanks
Direct company coverage
iX Biopharma Shifts Production Gear to U.S. to Support Wafermine Contract and Growth Push
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 16 Jun 2026 09:01
- Source
- TipRanks
marketscreener.com
Direct company coverage
IX Biopharma to Relocate Manufacturing Equipment to US; Shares Fall 8%
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 16 Jun 2026 04:43
- Source
- marketscreener.com
simplywall.st
Direct company coverage
Ix Biopharma (Catalist:42C) Narrowing H1 EPS Loss Challenges Bearish Earnings Narratives
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 10 May 2026 07:00
- Source
- simplywall.st
Minichart
Direct company coverage
iX Biopharma EGM 2026: Performance Share Vesting Terms for Mr Eddy Lee Yip Hang Explained
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Minichart
Market source
Direct company coverage
iX Biopharma’s Lee and wife Tang sell 13 mil shares on two different occasions
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Apr 2026 07:00
- Source
- Market source
NextInsight
Direct company coverage
iX Biopharma: Broker Issues Rare 5X Target. How Did It Arrive At That?
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 12 Apr 2026 07:00
- Source
- NextInsight
Market source
Direct company coverage
iX Biopharma issues 10 mil new ordinary shares at exercise price of six cents each
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Apr 2026 07:00
- Source
- Market source
Singapore Business Review
Direct company coverage
iX Biopharma gets SGX nod to list 75.8 million shares in $6m placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Feb 2026 08:00
- Source
- Singapore Business Review
Minichart
Direct company coverage
iX Biopharma Receives SGX Approval for S$6 Million Share Placement and Listing of 75.8 Million New Shares
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 19 Feb 2026 08:00
- Source
- Minichart
Minichart
Direct company coverage
iX Biopharma Announces S$6 Million Share Placement to Fund U.S. Government Contract Execution
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 12 Feb 2026 08:00
- Source
- Minichart
Singapore Business Review
Direct company coverage
iX Biopharma narrows losses in H1 FY 2026 despite 14% fall in revenue
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 10 Feb 2026 08:00
- Source
- Singapore Business Review
Market source
Direct company coverage
iX Biopharma reports lower net loss for 1HFY2026
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 08 Feb 2026 08:00
- Source
- Market source
Market source
Direct company coverage
iX Biopharma Ltd.'s (Catalist:42C) most bullish insider, CEO Yip Hang Lee must be pleased with the recent 15% gain
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 31 Dec 2025 08:00
- Source
- Market source
Singapore Business Review
Direct company coverage
iX Biopharma to raise at least $5m via OCBC share placement
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Oct 2025 07:00
- Source
- Singapore Business Review
Singapore Business Review
Direct company coverage
iX Biopharma upsizes placement to raise $6.7m
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Oct 2025 07:00
- Source
- Singapore Business Review
TradingView
Direct company coverage
Technical Analysis of iX Biopharma Ltd. (SGX:42C)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Feb 2018 18:42
- Source
- TradingView